JP2016521256A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016521256A5 JP2016521256A5 JP2016503215A JP2016503215A JP2016521256A5 JP 2016521256 A5 JP2016521256 A5 JP 2016521256A5 JP 2016503215 A JP2016503215 A JP 2016503215A JP 2016503215 A JP2016503215 A JP 2016503215A JP 2016521256 A5 JP2016521256 A5 JP 2016521256A5
- Authority
- JP
- Japan
- Prior art keywords
- asparagine
- alkyl
- aryl
- heterocyclyl
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- SCWQOYNSFXYAEZ-OQSGQEIMSA-N CC(C)[C@@H](C(N[C@@H](CCCNC(N)=O)C(Nc1ccc(CNC(SCCC(N(C)[C@@H](C)C(O[C@@H](CC(N(C)c2c(C)c(OC)cc(C/C(/C)=C/C=C/[C@H]([C@@](C3)(N4)O)OC)c2)=O)[C@]2(C)O[C@H]2[C@H](C)[C@H]3OC4=O)=O)=O)=S)cc1)=O)=O)NC(CCCCCN(C(C=C1)=O)C1=O)=O Chemical compound CC(C)[C@@H](C(N[C@@H](CCCNC(N)=O)C(Nc1ccc(CNC(SCCC(N(C)[C@@H](C)C(O[C@@H](CC(N(C)c2c(C)c(OC)cc(C/C(/C)=C/C=C/[C@H]([C@@](C3)(N4)O)OC)c2)=O)[C@]2(C)O[C@H]2[C@H](C)[C@H]3OC4=O)=O)=O)=S)cc1)=O)=O)NC(CCCCCN(C(C=C1)=O)C1=O)=O SCWQOYNSFXYAEZ-OQSGQEIMSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361792216P | 2013-03-15 | 2013-03-15 | |
| US61/792,216 | 2013-03-15 | ||
| PCT/US2014/029757 WO2014145090A1 (en) | 2013-03-15 | 2014-03-14 | Biologically active molecules, conjugates thereof, and therapeutic uses |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019059070A Division JP2019135239A (ja) | 2013-03-15 | 2019-03-26 | 生物活性分子、そのコンジュゲート、及び治療用途 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016521256A JP2016521256A (ja) | 2016-07-21 |
| JP2016521256A5 true JP2016521256A5 (https=) | 2017-04-20 |
| JP6847388B2 JP6847388B2 (ja) | 2021-03-31 |
Family
ID=50933481
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016503215A Active JP6847388B2 (ja) | 2013-03-15 | 2014-03-14 | 生物活性分子、そのコンジュゲート、及び治療用途 |
| JP2019059070A Pending JP2019135239A (ja) | 2013-03-15 | 2019-03-26 | 生物活性分子、そのコンジュゲート、及び治療用途 |
| JP2021043270A Pending JP2021105007A (ja) | 2013-03-15 | 2021-03-17 | 生物活性分子、そのコンジュゲート、及び治療用途 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019059070A Pending JP2019135239A (ja) | 2013-03-15 | 2019-03-26 | 生物活性分子、そのコンジュゲート、及び治療用途 |
| JP2021043270A Pending JP2021105007A (ja) | 2013-03-15 | 2021-03-17 | 生物活性分子、そのコンジュゲート、及び治療用途 |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US10570151B2 (https=) |
| EP (2) | EP2968593B1 (https=) |
| JP (3) | JP6847388B2 (https=) |
| KR (1) | KR102306490B1 (https=) |
| CN (1) | CN105188766B (https=) |
| AU (1) | AU2014233385C1 (https=) |
| BR (1) | BR112015022585B1 (https=) |
| CA (1) | CA2902872A1 (https=) |
| CL (1) | CL2015002765A1 (https=) |
| EA (1) | EA038512B1 (https=) |
| ES (1) | ES2996807T3 (https=) |
| IL (1) | IL240418B (https=) |
| MA (1) | MA38496B2 (https=) |
| MX (1) | MX379256B (https=) |
| MY (1) | MY183572A (https=) |
| PH (1) | PH12015502131B1 (https=) |
| SG (1) | SG11201507481WA (https=) |
| WO (1) | WO2014145090A1 (https=) |
| ZA (1) | ZA201505813B (https=) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8542802B2 (en) | 2007-02-15 | 2013-09-24 | Global Tel*Link Corporation | System and method for three-way call detection |
| RU2015129800A (ru) | 2012-12-21 | 2017-01-30 | Биоэллаенс К. В. | Гидрофильные саморазрушающиеся линкеры и их конъюгаты |
| MX379256B (es) | 2013-03-15 | 2025-03-10 | Regeneron Pharma | Moleculas biologicamente activas, conjugados de las mismas, y usos terapeuticos. |
| TWI641620B (zh) | 2013-08-21 | 2018-11-21 | 再生元醫藥公司 | 抗－ｐｒｌｒ抗體及其用途 |
| US9545451B2 (en) | 2013-08-21 | 2017-01-17 | Regeneron Pharmaceuticals, Inc. | Anti-PRLR antibodies and methods for killing PRLR-expressing cells |
| KR102252925B1 (ko) | 2013-08-26 | 2021-05-18 | 리제너론 파마슈티칼스 인코포레이티드 | 마크롤라이드 디아스테레오머를 포함하는 약제학적 조성물, 이의 합성 방법 및 치료학적 용도 |
| AU2015229591B2 (en) * | 2014-03-11 | 2020-10-22 | Regeneron Pharmaceuticals, Inc. | Anti-EGFRvlll antibodies and uses thereof |
| CA2950155C (en) | 2014-06-02 | 2021-11-23 | Regeneron Pharmaceuticals, Inc. | Biologically active molecule conjugates, reagents and methods of manufacture, and therapeutic uses |
| SG11201610620UA (en) | 2014-06-20 | 2017-01-27 | Bioalliance Cv | Anti-folate receptor aplha (fra) antibody-drug conjugates and methods of using thereof |
| EA034950B1 (ru) * | 2015-03-27 | 2020-04-09 | Регенерон Фармасьютикалз, Инк. | Производные майтанзиноида, их конъюгаты и способы использования |
| CN106243127B (zh) | 2015-06-09 | 2021-01-26 | 凯惠科技发展(上海)有限公司 | 抗体药物偶联物、中间体、制备方法、药物组合物及应用 |
| MY189159A (en) | 2015-07-06 | 2022-01-29 | Regeneron Pharma | Multispecific antigen-binding molecules and uses thereof |
| SG11201805557SA (en) | 2016-01-08 | 2018-07-30 | Bioalliance Cv | Tetravalent anti-psgl-1 antibodies and uses thereof |
| WO2017132173A1 (en) * | 2016-01-25 | 2017-08-03 | Regeneron Pharmaceuticals, Inc. | Maytansinoid derivatives, conjugates thereof, and methods of use |
| JP2019513371A (ja) | 2016-04-01 | 2019-05-30 | アビディティー バイオサイエンシーズ エルエルシー | 核酸ポリペプチド組成物とその使用 |
| WO2017190079A1 (en) | 2016-04-28 | 2017-11-02 | Regeneron Pharmaceuticals, Inc. | Methods of making multispecific antigen-binding molecules |
| EP4067368A1 (en) | 2016-06-01 | 2022-10-05 | Athira Pharma, Inc. | Compounds |
| MX2019003325A (es) | 2016-09-23 | 2019-08-05 | Regeneron Pharma | Anticuerpos anti-steap2, conjugados anticuerpo-farmaco, y moleculas de fijacion al antigeno biespecificas que se fijan a steap2 y cd3, y usos de estos. |
| MY194596A (en) | 2016-09-23 | 2022-12-06 | Regeneron Pharma | Bi Specific Anti-Muc16-CD3 Antibodies And Anti-Muc16 Drug Conjugates |
| TWI782930B (zh) * | 2016-11-16 | 2022-11-11 | 美商再生元醫藥公司 | 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法 |
| WO2018102304A1 (en) | 2016-11-29 | 2018-06-07 | Regeneron Pharmaceuticals, Inc. | Methods of treating prlr positive breast cancer |
| MX2019008199A (es) | 2017-01-06 | 2019-11-25 | Avidity Biosciences Llc | Composiciones de acido nucleico polipeptido y metodos de induccion de la omision de exon. |
| KR20240074000A (ko) | 2017-02-28 | 2024-05-27 | 다이이찌 산쿄 가부시키가이샤 | 항 her3 항체-약물 콘주게이트 투여에 의한 egfr-tki 저항성의 비소세포 폐암의 치료 방법 |
| TW201836647A (zh) | 2017-04-06 | 2018-10-16 | 美商艾伯維有限公司 | 抗－ｐｒｌｒ抗體藥物軛合物（ａｄｃ）及其用途 |
| KR20250008984A (ko) | 2017-05-18 | 2025-01-16 | 리제너론 파마슈티칼스 인코포레이티드 | 사이클로덱스트린 단백질 약물 접합체 |
| FI3635009T3 (fi) | 2017-06-07 | 2026-04-07 | Regeneron Pharma | Koostumuksia ja menetelmiä entsyymien internalisoimiseksi |
| MX2019015057A (es) | 2017-06-23 | 2020-08-03 | Velosbio Inc | Inmunoconjugados de anticuerpos receptor huérfano similar al receptor tirosina cinasa 1 (ror1). |
| GB201711809D0 (en) | 2017-07-21 | 2017-09-06 | Governors Of The Univ Of Alberta | Antisense oligonucleotide |
| WO2019071028A1 (en) | 2017-10-04 | 2019-04-11 | Avidity Biosciences Llc | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF |
| MX2020004691A (es) | 2017-11-07 | 2020-08-20 | Regeneron Pharma | Enlazadores hidrofilicos para conjugados anticuerpo-farmaco. |
| JP7506601B2 (ja) | 2017-12-06 | 2024-06-26 | アビディティー バイオサイエンシーズ，インク． | 筋萎縮症と筋緊張性ジストロフィーを処置するための組成物および方法 |
| MX2020011487A (es) | 2018-04-30 | 2020-12-07 | Regeneron Pharma | Anticuerpos y moleculas biespecificas de union al antigeno que se unen a her2 y/o aplp2, conjugados y usos de estos. |
| EP3793591A1 (en) | 2018-05-17 | 2021-03-24 | Regeneron Pharmaceuticals, Inc. | Anti-cd63 antibodies, conjugates, and uses thereof |
| SG11202012257VA (en) * | 2018-06-26 | 2021-01-28 | Immunogen Inc | Immunoconjugates targeting adam9 and methods of use thereof |
| KR20210062005A (ko) | 2018-09-20 | 2021-05-28 | 다이이찌 산쿄 가부시키가이샤 | 항 her3 항체-약물 콘쥬게이트 투여에 의한 her3 변이암의 치료 |
| IL312067B2 (en) | 2018-12-21 | 2025-08-01 | Avidity Biosciences Inc | Anti-transferrin receptor antibodies and uses thereof |
| JPWO2020145228A1 (ja) * | 2019-01-07 | 2021-11-11 | アステラス製薬株式会社 | 配位子及びＣＥＡＣＡＭ５抗体Ｆａｂフラグメントからなる複合体 |
| US20220040319A1 (en) | 2019-02-21 | 2022-02-10 | Regeneron Pharmaceuticals, Inc. | Methods of treating ocular cancer using anti-met antibodies and bispecific antigen binding molecules that bind met |
| US12497615B2 (en) | 2019-04-25 | 2025-12-16 | Avidity Biosciences, Inc. | Nucleic acid compositions and methods of multi-exon skipping |
| JP7592034B2 (ja) | 2019-06-06 | 2024-11-29 | アビディティー バイオサイエンシーズ，インク． | 核酸ポリペプチド組成物およびその使用 |
| KR20220019259A (ko) | 2019-06-06 | 2022-02-16 | 어비디티 바이오사이언시스 인크. | Una 아미다이트 및 이의 용도 |
| US11896682B2 (en) | 2019-09-16 | 2024-02-13 | Regeneron Pharmaceuticals, Inc. | Radiolabeled MET binding proteins for immuno-PET imaging and methods of use thereof |
| US11814428B2 (en) * | 2019-09-19 | 2023-11-14 | Regeneron Pharmaceuticals, Inc. | Anti-PTCRA antibody-drug conjugates and uses thereof |
| AU2020381495A1 (en) | 2019-11-15 | 2022-05-19 | Seagen Inc. | Methods of treating HER2 positive breast cancer with tucatinib in combination with an anti-HER2 antibody-drug conjugate |
| AU2021210987A1 (en) | 2020-01-24 | 2022-08-04 | Regeneron Pharmaceuticals, Inc. | Protein-antiviral compound conjugates |
| IL295312A (en) | 2020-02-28 | 2022-10-01 | Regeneron Pharma | Bispecific antigen binding molecules that bind her2, and methods of use thereof |
| US11555190B2 (en) | 2020-03-19 | 2023-01-17 | Avidity Biosciences, Inc. | Compositions and methods of treating Facioscapulohumeral muscular dystrophy |
| AU2021241682B2 (en) | 2020-03-27 | 2026-02-12 | Avidity Biosciences, Inc. | Compositions and methods of treating muscle dystrophy |
| IL319200A (en) | 2020-04-16 | 2025-04-01 | Regeneron Pharma | Antibody-drug conjugates prepared using Diels-Alder compression methods |
| JPWO2022014698A1 (https=) | 2020-07-17 | 2022-01-20 | ||
| AU2021366691B2 (en) | 2020-10-22 | 2024-06-06 | Regeneron Pharmaceuticals, Inc. | Anti-FGFR2 antibodies and methods of use thereof |
| CA3198294A1 (en) | 2020-11-10 | 2022-05-19 | Thomas Nittoli | Selenium antibody conjugates |
| AU2022238571A1 (en) | 2021-03-18 | 2023-09-14 | Seagen Inc. | Selective drug release from internalized conjugates of biologically active compounds |
| EP4316527A1 (en) | 2021-03-31 | 2024-02-07 | MicroBiopharm Japan Co., Ltd. | Method for manufacturing antibody-drug conjugate and enzyme used for same |
| US20240180963A1 (en) | 2021-04-05 | 2024-06-06 | Altheia Science S.R.L. | Diagnosis and treatment of myeloid disorders and acute leukemias using novel tumor specific antigens |
| MX2024003266A (es) | 2021-09-16 | 2024-04-03 | Avidity Biosciences Inc | Composiciones y metodos de tratamiento de la distrofia muscular facioescapulohumeral. |
| AU2022422149A1 (en) | 2021-12-23 | 2024-08-01 | Mirecule, Inc. | Compositions for delivery of polynucleotides |
| US12071621B2 (en) | 2022-04-05 | 2024-08-27 | Avidity Biosciences, Inc. | Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping |
| CA3255414A1 (en) | 2022-04-05 | 2023-10-12 | Alhena Science S.R.L. | TREATMENT FOR MYELOID DISORDERS AND ACUTE LEUKEMIAS TARGETING NEW TUMOR-SPECIFIC ANTIGENS |
| KR20230144960A (ko) | 2022-04-07 | 2023-10-17 | 트윈피그바이오랩(주) | 신규 펩타이드 기반 면역항암제 |
| IL318625A (en) | 2022-07-29 | 2025-03-01 | Regeneron Pharma | Compositions and methods for transferrin receptor (TFR)-mediated delivery to brain and muscle |
| AU2023379457A1 (en) | 2022-11-14 | 2025-05-15 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes |
| WO2024248123A1 (ja) | 2023-06-02 | 2024-12-05 | 第一三共株式会社 | 抗ｈｅｒ３抗体－薬物コンジュゲートとｒａｓｇ１２ｃ阻害剤の組み合わせ |
| CN121794380A (zh) | 2023-06-27 | 2026-04-03 | 艾维迪提生物科学公司 | 使用prkag2靶向性抗体-寡核苷酸缀合物的组合物和方法 |
| WO2025007063A1 (en) | 2023-06-30 | 2025-01-02 | Avidity Biosciences, Inc. | Compositions and methods of using pln-targeting antibody-oligonucleotide conjugates |
Family Cites Families (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4307016A (en) | 1978-03-24 | 1981-12-22 | Takeda Chemical Industries, Ltd. | Demethyl maytansinoids |
| JPS5566585A (en) | 1978-11-14 | 1980-05-20 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20070258987A1 (en) | 2000-11-28 | 2007-11-08 | Seattle Genetics, Inc. | Recombinant Anti-Cd30 Antibodies and Uses Thereof |
| EP1258255A1 (en) | 2001-05-18 | 2002-11-20 | Boehringer Ingelheim International GmbH | Conjugates of an antibody to CD44 and a maytansinoid |
| US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
| EP1487493B1 (en) * | 2002-03-01 | 2010-01-20 | The Administrators of The Tulane Educational Fund | Conjugates of cytotoxic agents and biologically active peptides |
| US20090068178A1 (en) | 2002-05-08 | 2009-03-12 | Genentech, Inc. | Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin |
| US20110250133A1 (en) | 2003-01-13 | 2011-10-13 | Bracco Imaging S.P.A. | Gastrin releasing peptide compounds |
| US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
| US7276497B2 (en) | 2003-05-20 | 2007-10-02 | Immunogen Inc. | Cytotoxic agents comprising new maytansinoids |
| CN102558352A (zh) | 2003-06-27 | 2012-07-11 | 艾默根佛蒙特有限公司 | 针对表皮生长因子受体的缺失突变体的抗体及其使用 |
| GB0316294D0 (en) | 2003-07-11 | 2003-08-13 | Polytherics Ltd | Conjugated biological molecules and their preparation |
| AR048098A1 (es) | 2004-03-15 | 2006-03-29 | Wyeth Corp | Conjugados de caliqueamicina |
| JP4806680B2 (ja) | 2004-05-19 | 2011-11-02 | メダレックス インコーポレイテッド | 自己犠牲リンカー及び薬剤複合体 |
| KR20120064120A (ko) | 2004-06-01 | 2012-06-18 | 제넨테크, 인크. | 항체 약물 접합체 및 방법 |
| EP1817341A2 (en) | 2004-11-29 | 2007-08-15 | Seattle Genetics, Inc. | Engineered antibodies and immunoconjugates |
| PL1819359T3 (pl) | 2004-12-09 | 2015-08-31 | Janssen Biotech Inc | Immunokoniugaty skierowane przeciw integrynie, metody ich wytwarzania oraz ich zastosowanie |
| NZ563370A (en) * | 2005-06-20 | 2010-10-29 | Genentech Inc | Compositions and methods for the diagnosis and treatment of tumor |
| NZ565075A (en) | 2005-06-20 | 2011-05-27 | Psma Dev Company Llc | PSMA antibody-drug conjugates |
| WO2007021674A2 (en) | 2005-08-09 | 2007-02-22 | Millennium Pharmaceuticals, Inc. | Method of acylating maytansinol with chiral amino acids |
| EP3539572A1 (en) | 2005-08-24 | 2019-09-18 | ImmunoGen, Inc. | Process for preparing maytansinoid antibody conjugates |
| US7750116B1 (en) | 2006-02-18 | 2010-07-06 | Seattle Genetics, Inc. | Antibody drug conjugate metabolites |
| KR20140116546A (ko) * | 2006-10-27 | 2014-10-02 | 제넨테크, 인크. | 항체 및 면역접합체 및 이들의 용도 |
| JP5394246B2 (ja) * | 2007-03-30 | 2014-01-22 | ジェネンテック， インコーポレイテッド | 抗体及びイムノコンジュゲートとこれらの使用方法 |
| WO2008122039A2 (en) | 2007-04-02 | 2008-10-09 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Selenocysteine mediated hybrid antibody molecules |
| EP2144628B1 (en) | 2007-05-08 | 2012-10-17 | Genentech, Inc. | Cysteine engineered anti-muc16 antibodies and antibody drug conjugates |
| JP2010528285A (ja) | 2007-05-23 | 2010-08-19 | ベンタナ・メデイカル・システムズ・インコーポレーテツド | 免疫組織化学およびｉｎｓｉｔｕハイブリダーゼーションのためのポリマー担体 |
| NZ602675A (en) | 2008-03-18 | 2014-03-28 | Genentech Inc | Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use |
| EP2276509B1 (en) * | 2008-04-11 | 2016-06-15 | Seattle Genetics, Inc. | Detection and tratment of pancreatic, ovarian and other cancers |
| KR20200058590A (ko) | 2008-04-30 | 2020-05-27 | 이뮤노젠 아이엔씨 | 가교제 및 그 용도 |
| EP2276506A4 (en) | 2008-04-30 | 2014-05-07 | Immunogen Inc | EFFICIENT CONJUGATES AND HYDROPHILIC BINDER |
| EP2374481B1 (en) | 2008-07-21 | 2015-11-04 | Polytherics Limited | Novel reagents and method for conjugating biological molecules |
| US9005598B2 (en) | 2009-03-04 | 2015-04-14 | Polytherics Limited | Conjugated proteins and peptides |
| WO2010120561A1 (en) * | 2009-04-01 | 2010-10-21 | Genentech, Inc. | Anti-fcrh5 antibodies and immunoconjugates and methods of use |
| JP5954789B2 (ja) | 2009-08-10 | 2016-07-20 | ユーシーエル ビジネス パブリック リミテッド カンパニー | 機能的分子の可逆的共有結合 |
| TW201116297A (en) | 2009-10-02 | 2011-05-16 | Sanofi Aventis | Antibodies that specifically bind to the EphA2 receptor |
| AR078471A1 (es) | 2009-10-02 | 2011-11-09 | Sanofi Aventis | COMPUESTOS MAITANSINOIDES Y EL USO DE ESTOS PARA PREPARAR CONJUGADOS CON UN ANTICUERPO LOS CUALES SE UTILIZAN COMO AGENTES ANTICANCERIGENOS Y EL PROCEDIMIENTO DE PREPARACIoN DE ESTOS CONJUGADOS |
| EP2486023A4 (en) | 2009-10-06 | 2014-05-07 | Immunogen Inc | EFFICIENT CONJUGATES AND HYDROPHILIC BINDER |
| MY173390A (en) * | 2009-10-23 | 2020-01-22 | Takeda Pharmaceuticals Co | Anti-gcc antibody molecules and related compositions and methods |
| US8501692B2 (en) | 2009-12-14 | 2013-08-06 | The Regents Of The University Of Michigan | Compositions and methods for altering cocaine esterase activity |
| DK2528625T3 (da) | 2010-04-15 | 2013-10-14 | Spirogen Sarl | Pyrrolobenzodiazepiner og konjugater deraf |
| US20130244905A1 (en) | 2010-07-06 | 2013-09-19 | Ed Grabczyk | Reporter for RNA Polymerase II Termination |
| SG10201912639SA (en) | 2010-08-02 | 2020-02-27 | Regeneron Pharma | Mice that make binding proteins comprising vl domains |
| MY162780A (en) | 2010-09-01 | 2017-07-14 | Bayer Ip Gmbh | N-(Tetrazol-5-yl)- and N-(triazol-5-yl)arylcarboxamides and use thereof as herbicides |
| CN105399831A (zh) | 2010-10-29 | 2016-03-16 | 伊缪诺金公司 | 非拮抗性egfr结合分子及其免疫偶联物 |
| CN103269712B (zh) | 2010-11-03 | 2016-09-21 | 伊缪诺金公司 | 包含新型安丝菌素衍生物的细胞毒性剂 |
| JP5889912B2 (ja) * | 2010-11-17 | 2016-03-22 | ジェネンテック， インコーポレイテッド | アラニニルメイタンシノール抗体コンジュゲート |
| JP6215194B2 (ja) | 2011-05-16 | 2017-10-18 | コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． | 生体直交型薬物活性化 |
| KR20140037105A (ko) | 2011-05-27 | 2014-03-26 | 암브룩스, 인코포레이티드 | 비-천연 아미노산 연결된 돌라스타틴 유도체를 함유하는 조성물, 이를 수반하는 방법, 및 용도 |
| US8815226B2 (en) | 2011-06-10 | 2014-08-26 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| CN103648532A (zh) | 2011-06-21 | 2014-03-19 | 伊缪诺金公司 | 具有肽连接子的新型美登木素生物碱衍生物及其偶联物 |
| CA2850103C (en) | 2011-10-14 | 2019-09-10 | Spirogen Sarl | Pyrrolobenzodiazepines |
| ES2945932T3 (es) | 2011-10-14 | 2023-07-10 | Seagen Inc | Pirrolobenzodiazepinas y conjugados dirigidos |
| WO2013055993A1 (en) | 2011-10-14 | 2013-04-18 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
| CA2850096C (en) | 2011-10-14 | 2018-07-03 | Spirogen Sarl | Synthesis method and intermediates useful in the preparation of pyrrolobenzodiazepines |
| WO2013068874A1 (en) | 2011-11-11 | 2013-05-16 | Pfizer Inc. | Antibody-drug conjugates |
| HK1202252A1 (en) | 2011-11-16 | 2015-09-25 | Amgen Inc. | Methods of treating epidermal growth factor deletion mutant viii related disorders |
| CN104244718A (zh) | 2011-12-05 | 2014-12-24 | 伊格尼卡生物治疗公司 | 抗体-药物缀合物以及相关化合物、组合物和方法 |
| GB201210770D0 (en) | 2012-06-18 | 2012-08-01 | Polytherics Ltd | Novel conjugation reagents |
| MX2014015682A (es) | 2012-06-19 | 2015-07-23 | Polytherics Ltd | Proceso novedoso para preparacion de conjugados de anticuerpo y conjugados de anticuerpo novedosos. |
| FI2911699T4 (fi) * | 2012-10-23 | 2025-12-09 | Synaffix Bv | Muokattu vasta-aine, vasta-ainekonjugaatti ja menetelmä niiden valmistamiseksi |
| NO2789793T3 (https=) | 2012-10-24 | 2018-01-27 | ||
| US10131682B2 (en) | 2012-11-24 | 2018-11-20 | Hangzhou Dac Biotech Co., Ltd. | Hydrophilic linkers and their uses for conjugation of drugs to a cell binding molecules |
| TW201425336A (zh) | 2012-12-07 | 2014-07-01 | Amgen Inc | Ｂｃｍａ抗原結合蛋白質 |
| CN104688740A (zh) | 2012-12-21 | 2015-06-10 | 百奥泰生物科技(广州)有限公司 | 类美登素衍生物及其制备方法和用途 |
| CN103254213B (zh) | 2012-12-21 | 2015-02-25 | 百奥泰生物科技(广州)有限公司 | 类美登素酯的制备方法及用于所述方法的组合物 |
| MX379256B (es) | 2013-03-15 | 2025-03-10 | Regeneron Pharma | Moleculas biologicamente activas, conjugados de las mismas, y usos terapeuticos. |
| CN103254311B (zh) | 2013-05-09 | 2015-05-13 | 齐鲁制药有限公司 | 一种制备抗体-美登素类生物碱药物偶联物的方法 |
| WO2014194030A2 (en) | 2013-05-31 | 2014-12-04 | Immunogen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
| US11229711B2 (en) | 2013-06-06 | 2022-01-25 | Magenta Therapeutics, Inc. | Linkers for antibody-drug conjugates and related compounds, compositions, and methods of use |
| SG11201509982UA (https=) | 2013-06-06 | 2016-04-28 | Igenica Biotherapeutics Inc | |
| WO2014197871A2 (en) | 2013-06-06 | 2014-12-11 | Igenica Biotherapeutics, Inc. | Antibody-drug conjugates, compositions and methods of use |
| US10781259B2 (en) | 2013-06-06 | 2020-09-22 | Magenta Therapeutics, Inc. | Modified antibodies and related compounds, compositions, and methods of use |
| US9545451B2 (en) | 2013-08-21 | 2017-01-17 | Regeneron Pharmaceuticals, Inc. | Anti-PRLR antibodies and methods for killing PRLR-expressing cells |
| KR102252925B1 (ko) | 2013-08-26 | 2021-05-18 | 리제너론 파마슈티칼스 인코포레이티드 | 마크롤라이드 디아스테레오머를 포함하는 약제학적 조성물, 이의 합성 방법 및 치료학적 용도 |
| WO2015081281A1 (en) | 2013-11-26 | 2015-06-04 | Segway Orthopaedics, Inc. | Surgical blade with viewing aperture |
| WO2015081282A1 (en) * | 2013-11-27 | 2015-06-04 | Redwood Bioscience, Inc. | Hydrazinyl-pyrrolo compounds and methods for producing a conjugate |
| US9562059B2 (en) | 2013-12-02 | 2017-02-07 | Hong Kong Baptist University | Anticancer maytansinoids with two fused macrocyclic rings |
| CA2950155C (en) | 2014-06-02 | 2021-11-23 | Regeneron Pharmaceuticals, Inc. | Biologically active molecule conjugates, reagents and methods of manufacture, and therapeutic uses |
| EA034950B1 (ru) | 2015-03-27 | 2020-04-09 | Регенерон Фармасьютикалз, Инк. | Производные майтанзиноида, их конъюгаты и способы использования |
| WO2017132173A1 (en) | 2016-01-25 | 2017-08-03 | Regeneron Pharmaceuticals, Inc. | Maytansinoid derivatives, conjugates thereof, and methods of use |
| MX2019003325A (es) | 2016-09-23 | 2019-08-05 | Regeneron Pharma | Anticuerpos anti-steap2, conjugados anticuerpo-farmaco, y moleculas de fijacion al antigeno biespecificas que se fijan a steap2 y cd3, y usos de estos. |
| US11814428B2 (en) | 2019-09-19 | 2023-11-14 | Regeneron Pharmaceuticals, Inc. | Anti-PTCRA antibody-drug conjugates and uses thereof |
-
2014
- 2014-03-14 MX MX2015011348A patent/MX379256B/es unknown
- 2014-03-14 EA EA201500905A patent/EA038512B1/ru unknown
- 2014-03-14 WO PCT/US2014/029757 patent/WO2014145090A1/en not_active Ceased
- 2014-03-14 JP JP2016503215A patent/JP6847388B2/ja active Active
- 2014-03-14 ES ES14729755T patent/ES2996807T3/es active Active
- 2014-03-14 AU AU2014233385A patent/AU2014233385C1/en active Active
- 2014-03-14 EP EP14729755.0A patent/EP2968593B1/en active Active
- 2014-03-14 SG SG11201507481WA patent/SG11201507481WA/en unknown
- 2014-03-14 CA CA2902872A patent/CA2902872A1/en active Pending
- 2014-03-14 CN CN201480025356.9A patent/CN105188766B/zh active Active
- 2014-03-14 MY MYPI2015002247A patent/MY183572A/en unknown
- 2014-03-14 BR BR112015022585-3A patent/BR112015022585B1/pt active IP Right Grant
- 2014-03-14 KR KR1020157028418A patent/KR102306490B1/ko active Active
- 2014-03-14 MA MA38496A patent/MA38496B2/fr unknown
- 2014-03-14 EP EP21194635.5A patent/EP3964237B1/en active Active
- 2014-03-14 US US14/776,668 patent/US10570151B2/en active Active
-
2015
- 2015-08-06 IL IL240418A patent/IL240418B/en active IP Right Grant
- 2015-08-13 ZA ZA2015/05813A patent/ZA201505813B/en unknown
- 2015-09-15 PH PH12015502131A patent/PH12015502131B1/en unknown
- 2015-09-15 CL CL2015002765A patent/CL2015002765A1/es unknown
-
2019
- 2019-03-26 JP JP2019059070A patent/JP2019135239A/ja active Pending
-
2020
- 2020-01-10 US US16/740,312 patent/US11345715B2/en active Active
-
2021
- 2021-03-17 JP JP2021043270A patent/JP2021105007A/ja active Pending
-
2022
- 2022-04-29 US US17/733,974 patent/US12378258B2/en active Active
-
2025
- 2025-06-30 US US19/255,790 patent/US20260062423A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016521256A5 (https=) | ||
| TWI864472B (zh) | 抗體的特異性偶聯 | |
| ES2996807T3 (en) | Biologically active molecules, conjugates thereof, and therapeutic uses | |
| CN113423430B (zh) | 含支链连接子的鹅膏毒素偶联物 | |
| WO2020257998A1 (en) | A conjugate of a cytotoxic agent to a cell binding molecule with branched linkers | |
| CN115443134A (zh) | 细胞结合分子与喜树碱类似物的偶联物 | |
| ES2781523T3 (es) | Conjugados de moléculas de unión celular con agentes citotóxicos | |
| JP2024023191A (ja) | 架橋ピロロベンゾジアゼピン二量体（ｐｂｄ）誘導体及びその共役体 | |
| NZ795845A (en) | A conjugate of a tubulysin analog with branched linkers | |
| BR112021006160A2 (pt) | composto conjugado, célula tumoral, composição farmacêutica, e, agentes sinérgicos | |
| EP3791897A1 (en) | Hsp90 inhibitor drug conjugates | |
| KR20170083998A (ko) | 유도형질로 활성화되는 다기능성 항암제 전구체, 이의 제조방법 및 이의 용도 | |
| JP2016523825A (ja) | 腎毒性活性物質からの保護のための接合体 | |
| KR20260014538A (ko) | 항체-약물 접합체에 의한 전립선암 및 다른 종양의 표적 치료 | |
| TW202540145A (zh) | 胜肽及包含該胜肽之偶聯物 | |
| KR20210068060A (ko) | 주사용 조성물 | |
| JP7853711B2 (ja) | チューブリシン類縁体と細胞結合分子との共役体の製剤 | |
| JP2015120657A (ja) | ペプチド及びヒト肝細胞選択的薬物送達複合体 | |
| CA3105541C (en) | Cross-linked pyrrolobenzodiazepine dimer (pbd) derivative and its conjugates | |
| EA048944B1 (ru) | Сшитое производное димера пирролобензодиазепина (pbd) и его конъюгаты | |
| NZ710814B2 (en) | Biologically active molecules, conjugates thereof, and therapeutic uses |